Castle Biosciences, Inc.
As of Oct 22, 2026, Castle Biosciences is in Stage 2, the uptrend phase, now in week 6 (since Sep 15, 2026). It closed at $33.19, 22.9% below its 52-week high and above its 200-day average, which is falling.
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Setup-score rank among Stage 2 peers: #1 of 32 in Diagnostics & Research · #1 of 272 in Health Care
Is CSTL early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
CSTL among Diagnostics & Research11th of 44 by relative strength
All 44 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CDNA | Stage 2 · wk 24 | 99 | +27.3% |
| 2 | BDSX | Stage 2 · wk 18 | 98 | −18.3% |
| 3 | ILMN | Stage 2 · wk 24 | 97 | +5.5% |
| 4 | GH | Stage 2 · wk 21 | 97 | −7.6% |
| 5 | NTRA | Stage 2 · wk 20 | 96 | +2.7% |
| 6 | CRL | Stage 2 · wk 16 | 92 | +22.5% |
| 7 | RVTY | Stage 2 · wk 18 | 90 | +10.7% |
| 8 | PSNL | Stage 2 · wk 17 | 90 | −3.2% |
| …11 | CSTL | Stage 2 · wk 6 | 83 | −4.8% |
Castle Biosciences: quick answers
What stage is Castle Biosciences in?
As of Oct 22, 2026, Castle Biosciences (CSTL) is in Stage 2, the uptrend phase. It entered Stage 2 on Sep 15, 2026 and is in week 6. What the four stages mean
Is Castle Biosciences in an uptrend?
Yes. Castle Biosciences is in a Stage 2 uptrend. It trades 15.8% above its 200-day average, which is falling.
How far is Castle Biosciences from its 52-week high?
Castle Biosciences closed at $33.19 on Oct 22, 2026, 22.9% below its 52-week high of $43.04. Its 52-week low is $18.15.
How has Castle Biosciences performed over the past year?
As of Oct 22, 2026, Castle Biosciences is up 41.8% over the past year and down 13.9% so far in 2026.
Which sector and industry is Castle Biosciences in?
Castle Biosciences is in the Diagnostics & Research industry, part of the Health Care sector.
About this companyHealth Care· Diagnostics & Research
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.